This report describes different types of biomarkers and their discovery using various "-omics" technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarkers.
This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as the development has increased remarkably since the beginning of the 21st century.
Currently, the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for the diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for the development of therapeutics.
Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in the use of pharmacogenetics, pharmacogenomics, and pharmacoproteomics for the development of personalized medicine.
Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics, and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials are discussed.
Biomarker markets are estimated from 2020 to 2030 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.
A large number of companies with varying technical backgrounds are involved in biomarkers and 300+ of these are profiled in part 2 of the report with classification into various categories. These also include major pharmaceutical companies.
Markets for Biomarkers
Biomarker markets according to technologies/applications
Markets for protein biomarkers
Biomarker market relevant to drug discovery and development
Proteomic biomarker-based drug discovery
Biomarker market relevant to epigenetics
Biomarker market relevant to bioinformatics
Biomarker markets according to therapeutic areas
Markets for cancer biomarkers
Geographical distribution of biomarker markets
Drivers for the growth of markets for biomarkers
Factors that enhance the value of biomarker IP
US policy on patenting relevant to biomarkers
US legal decisions on gene patenting
Strategies for developing biomarker markets
Utilization of biomarker research in academic laboratories.
Biomarker discovery at pharmaceutical companies
Industrial-academic collaborations in biomarkers
Unfulfilled needs in biomarkers
Challenges facing the biomarker industry
Application of biomarkers in healthcare
Applications of biomarkers beyond healthcare
Biomarkers for monitoring human exposure to environmental toxins
Key Topics Covered:
Part 1: Technologies & Applications
2. Technologies for Discovery of Biomarkers
3. Biomarkers and Molecular Diagnostics
4. Biomarkers for Drug Discovery & Development
5. Role of Biomarkers in Healthcare
6. Biomarkers in Metabolic Disorders
7. Biomarkers in Immune Disorders
8. Biomarkers of Musculoskeletal Disorders
9. Biomarkers of Infectious Diseases
10. Biomarkers of Genetic Disorders
11. Biomarkers of Aging
12. Nutritional Biomarkers
13. Biomarkers of Cancer
14. Biomarkers of Disorders of the Nervous System
15. Biomarkers of Cardiovascular Disorders
16. Biomarkers of Pulmonary Diseases
17. Biomarkers in Gynecology and Obstetrics
18. Biomarkers & Personalized Medicine
19. Biomarkers and Regulatory issues
Part II: Markets & Companies
21. Markets for Biomarkers
For more information about this report visit https://www.researchandmarkets.com/r/gn045p
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005530/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900